Iovance Biotherapeutics Inc
F:2LB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Iovance Biotherapeutics Inc
F:2LB
|
US |
|
P
|
Palo Alto Networks Inc
SWB:5AP
|
US |
|
P
|
Pernod Ricard SA
XHAM:PER
|
FR |
|
L
|
Link Real Estate Investment Trust
SWB:L5R
|
HK |
|
W
|
WW International Inc
XMUN:WW6
|
US |
|
Fujikura Ltd
OTC:FKURF
|
JP |
|
I
|
Intesa Sanpaolo SpA
XHAM:IES
|
IT |
|
Mincon Group PLC
LSE:MCON
|
IE |
|
Aena SME SA
MAD:AENA
|
ES |
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
M&T Bank Corp
F:MTZ
|
US |
|
I
|
II-VI Inc
XBER:II6
|
US |
|
Nine Dragons Paper (Holdings) Ltd
HKEX:2689
|
HK |
|
E
|
Eli Lilly and Co
XBER:LLY
|
US |
|
P
|
Polski Koncern Naftowy Orlen SA
XBER:PKY1
|
PL |
Iovance Biotherapeutics Inc
Iovance Biotherapeutics develops cell therapies for cancer, with a focus on tumor-infiltrating lymphocyte, or TIL, treatments. These are personalized medicines made from a patient’s own immune cells, expanded in the lab, and given back as a treatment that can help the body attack tumors. The company’s main product work centers on making and commercializing these therapies for patients with certain solid tumors. Its customers are cancer treatment centers, oncologists, and hospitals that use its approved or future therapies for eligible patients. Iovance makes money mainly by selling these cell therapies and, where needed, by supporting the specialized manufacturing and treatment process that goes with them. Because these medicines are complex and individualized, the company sits at the intersection of drug development, cell manufacturing, and oncology care. What makes Iovance different is that it is not selling a standard pill or broad chemotherapy regimen. It is building a highly specialized business around harvesting a patient’s own immune cells, processing them in a controlled facility, and returning a custom therapy back to the clinic. That makes its role in the cancer market closer to a cell-therapy manufacturer and treatment partner than a traditional drug company.
Iovance Biotherapeutics develops cell therapies for cancer, with a focus on tumor-infiltrating lymphocyte, or TIL, treatments. These are personalized medicines made from a patient’s own immune cells, expanded in the lab, and given back as a treatment that can help the body attack tumors. The company’s main product work centers on making and commercializing these therapies for patients with certain solid tumors.
Its customers are cancer treatment centers, oncologists, and hospitals that use its approved or future therapies for eligible patients. Iovance makes money mainly by selling these cell therapies and, where needed, by supporting the specialized manufacturing and treatment process that goes with them. Because these medicines are complex and individualized, the company sits at the intersection of drug development, cell manufacturing, and oncology care.
What makes Iovance different is that it is not selling a standard pill or broad chemotherapy regimen. It is building a highly specialized business around harvesting a patient’s own immune cells, processing them in a controlled facility, and returning a custom therapy back to the clinic. That makes its role in the cancer market closer to a cell-therapy manufacturer and treatment partner than a traditional drug company.
Revenue: Iovance reported first-quarter revenue of $71 million, up roughly 45% year over year, driven by strong Amtagvi demand.
Outlook: Management guided second-quarter revenue to $86 million to $88 million and Amtagvi revenue to $79 million to $81 million, calling it the company’s best Amtagvi quarter to date.
Margins: Gross margin was about 41% in the first quarter, held back by one-time facility upgrade costs, but management said margins should improve through the rest of 2026.
Demand: Amtagvi demand remained strong despite a temporary manufacturing capacity reduction, with March the largest month ever for reported revenue and referral trends at an all-time high.
Pipeline: Iovance highlighted early Phase II endometrial cancer data with a 40% confirmed response rate and said it plans to pursue an expedited FDA pathway.
Cash: The company said disciplined spending and manufacturing changes extended its cash runway into 2028, with about $319 million in cash and equivalents at quarter-end.
